HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into a strategic partnership and licensing agreement with Synthego Corporation, a U.S.-based leading provider of CRISPR solutions for cell and gene therapy development. The agreement grants Synthego access to Huida’s high-fidelity Cas12 CRISPR nuclease (hfCas12Max), strengthening Synthego’s capabilities in the realm of genetic research and therapy.
Under the terms of the licensing agreement, HuidaGene has granted Synthego the rights to manufacture and commercialize the hfCas12Max nuclease and its optimized guide RNA (gRNA) for research purposes. Additionally, HuidaGene has granted Synthego the right to sublicense the nuclease for therapeutic applications, although the financial specifics of the deal remain undisclosed.
HuidaGene, known for its focus on advancing CRISPR-based genomic medicines, aims to leverage this partnership to enhance the global reach of its innovative biotechnologies. Synthego, with its expertise in developing CRISPR solutions, stands to benefit from Huida’s high-fidelity CRISPR technology, potentially accelerating the development of new therapies.- Flcube.com
